PEN-221
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PEN-221, covering 2021-12-14 to 2021-12-14. Get the full timeline:
Most recent: Clinical Trial Update: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers [Phase 1, Phase 2]